Search
for

    Sort by

    Community Join

    300-330 / 1000+ results

      community Insulins impact on androgen levels

      in Research/Science  16 upvotes 4 years ago
      Controlling insulin levels through intermittent fasting and a low glycemic diet may improve hair quality by reducing androgens. It's important to maintain proper nutrition, including electrolytes and protein, during fasting.

      community Latanoprost Availability – Canada

      in Treatment  2 upvotes 3 years ago
      Latanoprost for hair loss is available in Canada at Ford's Family Pharmacy in New Brunswick, with up to 0.03% concentration, six times stronger than glaucoma medication Xalatan.

      community RU58841 in Pumpkin Seed Oil (PSO)

      in Treatment  4 upvotes 1 year ago
      A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

      community GT-20029 should be much more superior than finasteride

      in Research/Science  45 upvotes 1 year ago
      GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

      community AnagenInc says GT20029 is possible now

      in Research/Science  117 upvotes 3 years ago
      AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

      community RU58841 carrier - PG/Ethanol vs KB solution?

      in Treatment  2 upvotes 4 years ago
      The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

      community Where are GT20029 phase II results?

      in Research/Science  3 upvotes 2 years ago
      The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

      community Ru-58841 or KX-826 (Pyrilutamide)?

      in Treatment  12 upvotes 3 years ago
      Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.

      community Galenic lotion. Science behind the components

      in Treatment  1 upvotes 9 months ago
      A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.

      community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

      in Treatment  30 upvotes 4 months ago
      A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

      community I am doing an experience with RU58841

      in Treatment 6 months ago
      The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

      community Best available SARD right now?

      in Treatment  3 upvotes 2 days ago
      The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

      community KX-826 1% Phase II Results from China Just Dropped

      in Research/Science  37 upvotes 8 months ago
      KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

      community GT20029 Big Phase 2 Update Results!

      in Research/Science  54 upvotes 4 months ago
      GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

      community Looking for Latanoprost sources EU

      in Product  2 upvotes 2 years ago
      The user has been using MinoxidilMax Latanoprost 0.01% and noticed an increase in hair density after years of stability on finasteride and minoxidil. They are seeking help to find a higher dosage of Latanoprost or a reliable source to purchase the powder to make their own, without a prescription or high cost.

      community Veradermics VDPHL01: why isn’t anyone talking about it?

      in Treatment  42 upvotes 1 year ago
      Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

      community Quote from Pelage (PP-405) Spokesperson...

      in Research/Science  122 upvotes 6 months ago
      Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.